SULFONAMIDES DUPLEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SULFONAMIDES DUPLEX (SULFONAMIDES DUPLEX).
Sulfonamides are competitive antagonists of para-aminobenzoic acid (PABA) and inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
| Metabolism | Hepatic metabolism via N-acetylation and glucuronidation; CYP450 involvement is minimal. |
| Excretion | Renal: 70-100% unchanged drug via glomerular filtration and tubular secretion; fecal/biliary: <5%. |
| Half-life | Terminal half-life: 7-12 hours in patients with normal renal function; prolonged to 24-50 hours in renal impairment (CrCl <30 mL/min) due to reduced elimination. |
| Protein binding | 70-90% bound primarily to albumin, with variable binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.15-0.2 L/kg, indicating limited extravascular distribution; higher Vd in neonates and critically ill patients. |
| Bioavailability | Oral: 85-100% for short-acting sulfonamides; variable (50-80%) for sustained-release formulations. |
| Onset of Action | Oral: 1-2 hours (peak plasma concentration 2-6 hours); IV: immediate (within minutes). |
| Duration of Action | Oral: 6-12 hours (depends on formulation and renal function); sustained-release formulations may extend to 24 hours. |
Oral: 500-1000 mg twice daily; maximum 2000 mg/day.
| Dosage form | SUSPENSION |
| Renal impairment | CrCl 30-50 mL/min: 500 mg twice daily; CrCl 15-29 mL/min: 500 mg once daily; CrCl <15 mL/min: avoid use. |
| Liver impairment | Child-Pugh Class A: no adjustment; Class B: 500 mg twice daily; Class C: avoid use. |
| Pediatric use | 2 months to 12 years: 20-30 mg/kg/day divided every 12 hours; maximum 1000 mg/day. |
| Geriatric use | Initial dose 500 mg twice daily; monitor renal function and adjust accordingly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SULFONAMIDES DUPLEX (SULFONAMIDES DUPLEX).
| Breastfeeding | Sulfonamides are excreted into breast milk in low concentrations (M/P ratio approximately 0.5-0.7). Risk of kernicterus in neonates, especially in premature or jaundiced infants or those with G6PD deficiency. Avoid breastfeeding if alternative agents are available; if used, monitor infant for jaundice, hemolysis, and rash. |
| Teratogenic Risk | First trimester: Possible increased risk of neural tube defects and cardiovascular anomalies based on animal studies and limited human data. Second and third trimesters: Risk of kernicterus in neonates due to bilirubin displacement from albumin; avoid near term. Sulfonamides are generally avoided in pregnancy due to potential for hemolytic anemia in glucose-6-phosphate dehydrogenase (G6PD)-deficient fetuses and maternal hypersensitivity. |
■ FDA Black Box Warning
Sulfonamides have been associated with fatal hypersensitivity reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis.
| Serious Effects |
Hypersensitivity to sulfonamides, porphyria, severe hepatic or renal impairment, pregnancy (late term), and breastfeeding (if infant has hyperbilirubinemia or glucose-6-phosphate dehydrogenase deficiency).
| Precautions | Hypersensitivity reactions, hematologic toxicity (e.g., agranulocytosis), photosensitivity, hepatic injury, renal impairment, and kernicterus in neonates. |
Loading safety data…
| Fetal Monitoring | Monitor maternal complete blood count, renal function, and liver function tests. Fetal ultrasound for anomaly assessment if used in first trimester. In late pregnancy, monitor neonatal bilirubin levels and signs of hemolysis or jaundice. Consider G6PD status in mother and family history before use. |
| Fertility Effects | No significant adverse effects on fertility reported in animal or human studies. Sulfonamides may cause reversible oligospermia in males with prolonged use, but overall impact on fertility is minimal. |